ReviewCurrent opinion in infectious diseases2009
Treatment of cryptococcal meningitis in resource limited settings.
Review in Current opinion in infectious diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.PloS one · 2013Pooled it
- Investigating the therapeutic potential of the antibacterial drug nitroxoline in combating cryptococcal infection.PLoS neglected tropical diseases · 2026Article
- Assessment of Clinical Guideline Use in the Prevention, Diagnosis, and Treatment of Cryptococcal Meningitis Among Health Care Providers in Ethiopia.Open forum infectious diseases · 2025Article
- Antifungal Activity of 8-Hydroxyquinoline Derivatives AgainstPathogens (Basel, Switzerland) · 2025Article
- 'WhenTherapeutic advances in chronic disease · 2022Article
- Re-emerging Aspartic Protease Targets: ExaminingJournal of medicinal chemistry · 2021Article
- The Added Value of Longitudinal Imaging for PreclinicalAntimicrobial agents and chemotherapy · 2020Article
- A Highly Active Triterpene Derivative Capable |of Biofilm Damage to ControlBiomolecules · 2019Article
- Fungal Kinases With a Sweet Tooth: Pleiotropic Roles of Their Phosphorylated Inositol Sugar Products in the Pathogenicity ofFrontiers in cellular and infection microbiology · 2019Review
- Population Pharmacokinetic Modeling to Describe the Total Plasma and Free Brain Levels of Fluconazole in Healthy and Cryptococcus neoformans Infected Rats: How Does the Infection Impact the Drug's Levels on Biophase?Pharmaceutical research · 2018Article
- Antifungal Phenothiazines: Optimization, Characterization of Mechanism, and Modulation of Neuroreceptor Activity.ACS infectious diseases · 2018Article
- Recurrence of Cryptococcal Meningitis and the Hidden Role of Patient Education and Social Support.Case reports in neurological medicine · 2018Article
- HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for "Prevention Is Better Than Cure"?Journal of fungi (Basel, Switzerland) · 2017Review
- Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.Antimicrobial agents and chemotherapy · 2017Article
- The Anti-helminthic Compound Mebendazole Has Multiple Antifungal Effects againstFrontiers in microbiology · 2017Article
- The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.Antimicrobial agents and chemotherapy · 2016Article
- High-Throughput Screen inACS infectious diseases · 2016Article
- Article
- Structure-activity relationships for the antifungal activity of selective estrogen receptor antagonists related to tamoxifen.PloS one · 2015Article
- Antifungal drug development: challenges, unmet clinical needs, and new approaches.Cold Spring Harbor perspectives in medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
purpose of reviewCryptococcal meningitis most commonly occurs in advanced HIV. Although diminishing in the developed world with antiretroviral therapy (ART), it remains a major problem in resource-limited settings. ART rollout will improve long-term HIV survival if opportunistic infections are effectively treated. Considering cryptococcal meningitis in that context, this review addresses excess morbidity and mortality in developing countries, treatment in areas of limited drug availability and challenges posed by combined anticryptococcal and HIV therapy. RECENT
findingsFrom Early Fungicidal Activity (EFA) studies, amphotericin B-flucytosine is best induction therapy but often unavailable; high dose amphotericin B monotherapy may be feasible in some settings. Where fluconazole is the only option, higher doses are more fungicidal. Serum cryptococcal antigen testing may identify patients at highest disease risk and primary prophylaxis is effective; the clinical role of such interventions needs to be established. Timing of ART introduction remains controversial; early initiation risks Immune Reconstitution Disease (IRD) delays may increase mortality. SUMMARY: Amphotericin B based treatment is appropriate where possible. More studies are needed to optimize fluconazole monotherapy doses. Other research priorities include management of raised intracranial pressure, appropriate ART initiation and IRD treatment. Studies should focus on developing countries where problems are greatest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.